Headlines & Helpful Information
By: Amanda DeBard
The 2019 San Antonio Breast Cancer Symposium (SABCS) kicked
off with the presentation of two clinical trials that showed groundbreaking findings,
adding to the treatment options for people with HER2-positive metastatic breast
“This is a great result for HER2-positive metastatic breast
cancer patients, with and without brain metastasis,” said Dr. Sherene Loi, head of the Translational Breast Cancer Genomics and
Therapeutics Laboratory at Peter MacCallum Cancer Center in Melbourne,
Australia, who moderated the presentations.
The HER2CLIMB trial was unique in that it was open to
patients with brain metastasis, or the presence of breast cancer in the brain,
in addition to those without brain metastasis. Many clinical trials are not
open to patients with brain metastasis. This trial compared the use of
tucatinib to placebo in combination with trastuzumab and capecitabine in
patients with metastatic HER2-positive breast cancer.
Susan G. Komen Scientific Advisory Board Member Dr. Lisa
Carey was involved the HER2CLIMB trial and said, “the results in patients with
brain metastases are encouraging and show that we are gaining ground on this
She added that “tucatinib (added to capecitabine +
trastuzumab) appears poised to become the preferred next-line therapy after [trastuzumab
Loi said, “There is great need for treatment for patients
with brain metastasis. The data are very compelling; I would think this would
be practice changing.”
The results of HER2CLIMB study were published in the New
England Journal of Medicine, coinciding with release of the findings at
presentation focused on the DESTINY-Breast01
clinical trial. In this trial researchers tested the safety and efficacy of [fam]-trastuzumab
deruxtecan, an antibody drug conjugate for HER2-positive metastatic breast
cancer patients who have received two or more prior therapies.In fact,
patients on this study had received a median of six prior therapies.
The results show [fam]-trastuzumab deruxtecan as a potential new
option for those patients who will likely have exhausted most, if not all,
standard therapies for HER2-positive metastatic breast cancer.
Komen Scholar Dr. Ian Krop was involved in the trial and presented
These are just two clinical trials presented at SABCS with
significant implications for patients with breast cancer for which there is
currently no cure.
Komen Scholar Dr. Ian Krop.
Return to Blog Home